NexgenRx Dirección

Dirección controles de criterios 2/4

El CEO de NexgenRx es Ron Loucks , nombrado en Mar 2003, tiene una permanencia de 21.67 años. compensación anual total es CA$313.34K, compuesta por 75% salario y 25% primas, incluidas acciones y opciones de la empresa. posee directamente un 10.48% de las acciones de la empresa, por valor de CA$2.20M. La antigüedad media del equipo directivo y de la junta directiva es de 5.5 años y 12.5 años, respectivamente.

Información clave

Ron Loucks

Chief Executive Officer (CEO)

CA$313.3k

Compensación total

Porcentaje del salario del CEO	75.0%
Permanencia del CEO	21.7yrs
Participación del CEO	10.5%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	12.5yrs

Actualizaciones recientes de la dirección

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

Recent updates

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

May 21

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 10

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 19

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

Dec 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ron Loucks en comparación con los beneficios de NexgenRx?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CA$25k
Mar 31 2024	n/a	n/a	-CA$66k
Dec 31 2023	CA$313k	CA$235k	-CA$332k
Sep 30 2023	n/a	n/a	-CA$310k
Jun 30 2023	n/a	n/a	-CA$244k
Mar 31 2023	n/a	n/a	-CA$172k
Dec 31 2022	CA$287k	CA$235k	-CA$22k
Sep 30 2022	n/a	n/a	CA$3m
Jun 30 2022	n/a	n/a	CA$4m
Mar 31 2022	n/a	n/a	CA$4m
Dec 31 2021	CA$230k	CA$215k	CA$4m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$2m
Mar 31 2021	n/a	n/a	CA$2m
Dec 31 2020	CA$153k	CA$140k	CA$2m
Sep 30 2020	n/a	n/a	CA$1m
Jun 30 2020	n/a	n/a	CA$483k
Mar 31 2020	n/a	n/a	-CA$31k
Dec 31 2019	CA$181k	CA$165k	-CA$208k
Sep 30 2019	n/a	n/a	CA$38k
Jun 30 2019	n/a	n/a	-CA$147k
Mar 31 2019	n/a	n/a	-CA$438k
Dec 31 2018	CA$181k	CA$165k	-CA$697k
Sep 30 2018	n/a	n/a	-CA$1m
Jun 30 2018	n/a	n/a	-CA$1m
Mar 31 2018	n/a	n/a	-CA$793k
Dec 31 2017	CA$181k	CA$165k	-CA$626k

Compensación vs. Mercado: La compensación total de Ron($USD222.40K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD170.34K).

Compensación vs. Ingresos: La compensación de Ron ha aumentado mientras la empresa no es rentable.

CEO

Ron Loucks (74 yo)

21.7yrs

Permanencia

CA$313,342

Compensación

Mr. Ronald C. Loucks, also known as Ron, B.B.A. Founded NexgenRx, Inc. in March 2003 and has been its Chief Executive Officer and President since March 2003. Mr. Loucks has over 25 years of experience in t...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Kelly Elher	Chief Financial Officer	7.5yrs	CA$60.00k	0.63% CA$ 132.5k
Andrew Munroe	Vice President of Operations	less than a year	CA$169.40k	sin datos
Jason Robinson	Vice President of Administration	no data	sin datos	sin datos
Doreen Harvey	Lead Human Resources	no data	sin datos	sin datos
Paul Bolger	Company Secretary	3.4yrs	sin datos	sin datos
Avik Debroy	Financial Controller	no data	sin datos	sin datos

5.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de NXG es experimentado (5.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ronald Loucks	Founder	21.7yrs	CA$313.34k	10.48% CA$ 2.2m
Thomas Corcoran	Independent Chairman	18.7yrs	CA$30.00k	0.88% CA$ 184.5k
Linda Brennan	Director	less than a year	sin datos	sin datos
Randolf McGlynn	Independent Director	6.3yrs	CA$20.00k	0.14% CA$ 29.5k

12.5yrs

Permanencia media

74yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de NXG son experimentados ( 12.5 años antigüedad media).

NexgenRx Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

NexgenRx Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

Recent updates

NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of Directors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2023)

Dividend of CA$0.005 announced

NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024

Optimistic Investors Push NexgenRx Inc. (CVE:NXG) Shares Up 45% But Growth Is Lacking

First quarter 2024 earnings released: EPS: CA$0.006 (vs CA$0.003 in 1Q 2023)

Charles Burns Tenders Resignation as Director of NexgenRx Inc

We Discuss Why NexgenRx Inc.'s (CVE:NXG) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Full year 2023 earnings released: CA$0.005 loss per share (vs CA$0 in FY 2022)

NexgenRx Inc., Annual General Meeting, May 16, 2024

NexgenRx Inc.'s (CVE:NXG) Price Is Out Of Tune With Revenues

Insufficient new directors

NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of Directors

NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0 (vs CA$0 in 2Q 2022)

NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023

High number of new directors

First quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.005 in 1Q 2022)

NexgenRx Inc. Appoints Dave Bennett as New Director

Insufficient new directors

Full year 2022 earnings released

Here's Why We Think NexgenRx (CVE:NXG) Might Deserve Your Attention Today

Insufficient new directors

Now 23% undervalued

Third quarter 2022 earnings released

Insufficient new directors

Is Now The Time To Put NexgenRx (CVE:NXG) On Your Watchlist?

NexgenRx Inc. Announces Dividend on its outstanding common shares, payable on or Before October 10, 2022

NexgenRx Inc. Announces Dividend on its outstanding common shares, Payable on Payable on or Before October 10, 2022

Second quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.005 profit in 2Q 2021)

First quarter 2022 earnings released: EPS: CA$0.005 (vs CA$0.005 in 1Q 2021)

Insufficient new directors

NexgenRx Inc., Annual General Meeting, May 19, 2022

Full year 2021 earnings released: EPS: CA$0.055 (vs CA$0.029 in FY 2020)

Does NexgenRx (CVE:NXG) Deserve A Spot On Your Watchlist?

Third quarter 2021 earnings released: EPS CA$0.006 (vs CA$0.007 in 3Q 2020)

Insufficient new directors

What NexgenRx Inc.'s (CVE:NXG) 32% Share Price Gain Is Not Telling You

Second quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.007 in 2Q 2020)

Here's Why NexgenRx Inc.'s (CVE:NXG) CEO May Have Their Pay Bumped Up

First quarter 2021 earnings released: EPS CA$0.005 (vs CA$0.004 in 1Q 2020)

Full year 2020 earnings released: EPS CA$0.03 (vs CA$0.003 loss in FY 2019)

New 90-day high: CA$0.34

NexgenRx Inc.'s (CVE:NXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$0.30

How Much Is NexgenRx's (CVE:NXG) CEO Getting Paid?

New 90-day high: CA$0.23

Third quarter 2020 earnings released: EPS CA$0.007

NexgenRx Inc.(TSXV:NXG) dropped from S&P/TSX Venture Composite Index

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad